Old Web
English
Sign In
Acemap
>
authorDetail
>
Reshma A. Rangwala
Reshma A. Rangwala
Merck & Co.
Medicine
Oncology
Internal medicine
platinum resistant
Pathology
4
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.
2021
Journal of Clinical Oncology
Katherine Fuh
Michael A. Bookman
Robert L. Coleman
Thomas J. Herzog
Premal H. Thaker
Joyce F. Liu
Michelle W. Lane
Reshma A. Rangwala
Gail McIntyre
Bradley J. Monk
Kathleen N. Moore
Show All
Source
Cite
Save
Citations (0)
A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).
2021
Journal of Clinical Oncology
Katherine Fuh
Thomas J. Herzog
Kathleen N. Moore
Tashanna K.N. Myers
Bobbie J. Rimel
Joyce F. Liu
Angeles Alvarez Secord
Erika Hamilton
Thomas J. Reid
Sharyn N. Lewin
Mary M. Mullen
K.A. Mills
Randy Anderson
Reshma A. Rangwala
Show All
Source
Cite
Save
Citations (0)
Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer.
2013
Journal of Clinical Oncology
James T. Symanowski
E. Kutarska
Mariusz Bidziński
Binh Nguyen
Reshma A. Rangwala
R. Wendel Naumann
Show All
Source
Cite
Save
Citations (0)
1